Navigation Links
Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Date:12/6/2011

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

Forward Looking Statements

This statement contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10- Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
2. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
3. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
4. Amgen Announces 2011 Fourth Quarter Dividend
5. Amgen to Present at the UBS Global Life Sciences Conference
6. Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
7. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
8. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
9. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
10. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
11. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... intensively investigated for application as catalysts, sensors, ... components in photonics and molecular electronics. Gaining ... understanding physical and chemical properties, has been ... have demonstrated that high-resolution electron microscopy can ... in which all gold atoms are observed. ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... and China Gel Permeation Chromatography (GPC) Industry Report 2014" ... Global and China Gel Permeation Chromatography (GPC) Industry Report ... state of the global gel permeation chromatography industry with ... provides a basic overview of the industry including definitions, ...
(Date:8/22/2014)... Nerium International, the go-to, buzzworthy skincare ... again. Nerium will showcase its signature NeriumAD® Age-Defying ... Cream to Hollywood’s elite at the official Giving ... Primetime Emmy® Awards. , Developed from cutting-edge research ... show that NeriumAD night cream dramatically reduces the ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  BioSpecifics ... biopharmaceutical company developing first in class collagenase-based products ... or CCH) in the U.S. and XIAPEX ® ... significant results from a randomized, double-blind Phase 2a ... cellulite, or edematous fibrosclerotic panniculopathy. The results showed ...
Breaking Biology Technology:A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... a pair of information-carrying molecules: DNA and RNA. These ... they display hereditymeaning they can encode and pass on ... processes of Darwinian evolution. A long-debated question ... molecules other than DNA and RNA. John ...
... new applications based on nanoimprinting techniques (NIL) is evolving at ... be overcome in order to reach the market? How do ... from the industry? What are the tools needed for each ... this topic, i.e. Nanopatterning, Production and Applications based on Nanoimprinting ...
... April 19, 2012 RayBiotech, Inc. today announced that ... diagnostic core facilities at academic and government research institutes ... of the partnership program, core diagnostics facilities will be ... a component of their current services offerings at no ...
Cached Biology Technology:Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 2Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 3Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 4Low-cost optical components through nanoimprinting lithography 2Low-cost optical components through nanoimprinting lithography 3RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2
(Date:8/22/2014)... a leading source of information for businesses and professionals, ... Riverside in its 2014 list of "some of the ... generate the list, the company analyzed citation data over ... has had enormous impact. , The following UC Riverside ... the greatest number of highly cited papers in one ...
(Date:8/22/2014)... August 21, 2014 Diabetes affects nearly 10 ... complaints of diabetics: constant finger pricking to test ... Chemical Biology reports the development of a protein ... accurate results for diabetes patients. In the American ... Daunert, Ph.D., shows off her "designer protein" that ...
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
Breaking Biology News(10 mins):5 UC Riverside scientists among world's most influential scientific minds 2New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... Results from two French studies presented today at the ... clinical practice in the treatment of patients with severe ... demonstrated the positive potential of performing liver transplantation for ... the recommended 6-months rule (required minimum of recorded abstinence ...
... Results from two studies presented today at the International ... devices may not confer a survival advantage for severe ... among a small sub-group of patients show promise. ... is valued as a detoxification treatment option for patients ...
... for Chemoreception Sciences (AChemS), a US-based scientific organization, is ... gathering to present new information on the role of ... in humans as well as animals. Smell and taste ... senses serve as important warning systems, alerting us to ...
Cached Biology News:New insights into treatment options for patients suffering from severe alcoholic hepatitis 2New findings on taste and smell 2New findings on taste and smell 3
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Biology Products: